Actively Recruiting
Phase 3 Study of Solriamfetol for Treating Binge Eating Disorder in Adults Aged 18 to 55
Led by Axsome Therapeutics, Inc. · Updated on 2026-07-28
450
Participants Needed
45
Research Sites
N/A
Total Duration
AI-Summary
What this Trial Is About
Researchers are evaluating the effects and safety of solriamfetol in adults with binge eating disorder BED. This Phase 3 trial compares two doses of solriamfetol 150 mg and 300 mg with a placebo to better understand their impact on BED symptoms. Participants must be aged 18 to 55 with a diagnosis of BED based on DSM-5 criteria. Participants will be randomly assigned to one of three groups receiving either solriamfetol 150 mg, solriamfetol 300 mg, or placebo tablets, all taken once daily for 12 weeks. This randomized, double-blind study will assess how these treatments affect binge eating episodes over the course of the trial. During the 12 weeks, participants will be monitored for changes in the number of binge eating episodes. Safety and efficacy will be evaluated through regular assessments. All study-related care, including medication and visits, will be provided at no cost, and the total participation duration is approximately 12 weeks.
CONDITIONS
Brief Title
Elucidating TAAR-1, Dopamine, and Norepinephrine in Binge Eating Disorder Using Solriamfetol
Research Team
S
Study Director
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
